Theranostics 2017; 7(7):1940-1941. doi:10.7150/thno.20284

Editorial

Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Steve S. Huang, Warren D.W. Heston

Cancer Biology Department Lerner Research Institute, Cleveland Clinic Cleveland OH.

Abstract

Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the question of whether we can further increase the effectiveness of PSMA targeted therapy by adding an albumin-binding entity to low-molecular-weight agents

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Huang SS, Heston WDW. Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?. Theranostics 2017; 7(7):1940-1941. doi:10.7150/thno.20284. Available from http://www.thno.org/v07p1940.htm